Pfizer R&D VP interviewed on future drug delivery

There have been numerous advancements in drug formulation, delivery devices, and delivery methods since parenteral administration became the gold standard for drug delivery. In the interview just out at Pharmaceutical Technology, Pfizer’s vice president of pharmaceutical R&D, Nicholas W. Warne discussed advances in drug delivery, how small molecules differ from large molecules when delivered, what delivery technologies are most stable, what the future holds for biologics delivery (beyond intravenous, intramuscular, and subcutaneous injections), and how personalized medicine can contribute to drug delivery.

Related News

Willum Þór: The question remains if our healthcare system is sustainable

On January 1st, Iceland took over the Presidency of the Nordic Council of Ministers. This intergovernmental organisation plays an important role in promoting innovations, health data integration, and cooperation between all major stakeholders in the Nordic healthcare. The Icelandic Health Minister elaborates on his vision to future health in the Nordic region, the Nordic strengths, Iceland’s plans for the Presidency with regards to health innovations, and the coming collaboration with Copenhagen Institute for Futures Studies

CIFS launches a masterclass on future of health in primary care

This masterclass has been created to take you on an exploration of what healthcare will look like in 2035, exploring opportunities, challenges, and facilitators along the way. The course challenges your mindset through megatrends and futures methodologies for prioritizing initiatives for a healthier future

Drug Pricing and Reimbursement: Case for Decentralization

Decentralization has not yet been applied within the cryptic act of drug pricing. The key advances of decentralization in supply chains and clinical trials prove promising. Consensus reaching is crucial. Stakeholders are unlikely to favor transparency as that is the method by which they can fulfill their fiduciary responsibility in maximizing profits for companies. Therefore, without government intervention through stringent policy, stakeholders will not easily give up on rising profit margins

All News

Willum Þór: The question remains if our healthcare system is sustainable

On January 1st, Iceland took over the Presidency of the Nordic Council of Ministers. This intergovernmental organisation plays an important role in promoting innovations, health data integration, and cooperation between all major stakeholders in the Nordic healthcare. The Icelandic Health Minister elaborates on his vision to future health in the Nordic region, the Nordic strengths, Iceland’s plans for the Presidency with regards to health innovations, and the coming collaboration with Copenhagen Institute for Futures Studies

CIFS ran an all-day session at the Week of Health and Innovation (WHINN) in Odense

Copenhagen Institute for Futures Studies ran an all-day session at the annual Week of Health and Innovation (WHINN) in Odense, Denmark. CIFS’ program attracted over 40 experts from health and data organisations. We presented strategic foresight and futures studies in the health sector, concepts that are used to reimagine the future of the health sector, such as the Humanome and decentralised clinical trials. Also, we had a panel discussion on the newly started Phase V project on decentralised clinical trials, where CIFS is a contributing partner